Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 11/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SIK1 | P57059 | 1/20 | 0.42 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.42 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8233271 | 0.90 | FGFR1 (0.46) | HPGDFGFR1MEN1KMT2AALDH1A1 | |
| SCHEMBL2666424 | 0.90 | FGFR1 (0.46) | HPGDFGFR1MEN1KMT2AALDH1A1 | |
| SCHEMBL1616888 | 0.90 | FGFR1 (0.46) | HPGDFGFR1MEN1KMT2AALDH1A1 | |
| SCHEMBL2652008 | 0.90 | FGFR1 (0.46) | HPGDFGFR1MEN1KMT2AALDH1A1 | |
| SCHEMBL12415695 | 0.88 | FGFR1 (0.45) | HPGDFGFR1MEN1KMT2AALDH1A1 | |
| SCHEMBL12415697 | 0.88 | FGFR1 (0.45) | HPGDFGFR1MEN1KMT2AALDH1A1 | |
| SCHEMBL12716015 | 0.87 | FGFR1 (0.44) | HPGDFGFR1MEN1KMT2AALDH1A1 | |
| SCHEMBL2646018 | 0.85 | FGFR1 (0.58) | HPGDFGFR1 | |
| SCHEMBL22185374 | 0.84 | FGFR1 (0.65) | FGFR1ALDH1A1 | |
| SCHEMBL2652240 | 0.83 | FGFR1 (0.44) | HPGDFGFR1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062304-A1 | Benzimidazole derivatives and their use for modulating the gaba-alpha receptor complex | NEUROSEARCH A/S (DK) | 2009-03-05 | — | — | US | disclosed |
| US-20090062304-A1 | Benzimidazole derivatives and their use for modulating the gaba-alpha receptor complex | NEUROSEARCH A/S (DK) | 2009-03-05 | — | — | US | disclosed |
| US-20090062304-A1 | Benzimidazole derivatives and their use for modulating the gaba-alpha receptor complex | NEUROSEARCH A/S (DK) | 2009-03-05 | — | — | US | disclosed |
| WO-2006111517-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062304-A1 | Benzimidazole derivatives and their use for modulating the gaba-alpha receptor complex | GABRB1, GABRB2, GABRB3 | HPGD 2480/4885FGFR1 3792/4885MEN1 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.